About this trial
Ovarian cancer is a deadly disease that is hard to detect early and difficult to treat. Research shows that most ovarian cancers actually start in the fallopian tubes, not the ovaries. Removing the fallopian tubes (a procedure called salpingectomy) can lower the risk of ovarian cancer by about 80%. This procedure has no added risk to the patient, but does lead to sterilization and thus it is only offered to individuals who have completed child-bearing. Adding salpingectomy to another surgery that a patient is undergoing is called opportunistic salpingectomy and is already standard of practice in many gynecologic surgeries, such as hysterectomy. However, it is not yet commonly offered during weight-loss (bariatric) surgery, even though many patients having this surgery could benefit. This study will test whether it is practical and safe to offer fallopian tube removal during bariatric surgery at three hospitals in Canada. Patients who are eligible and interested will be invited to have their fallopian tubes removed at the same time as their planned weight-loss surgery. The research team will track whether the procedure can be completed successfully, whether there are any added complications, and how much extra time or resources are needed. The goal is to help make this cancer-prevention option available to more people.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Individuals with fallopian tubes (no prior salpingectomy/salpingo-oophorectomy) who are undergoing an elective MBS and have completed child-bearing
Disqualifiers
unable to provide informed consent
Trial design
Single group
Treatments tested in this trial
Opportunistic salpingectomy at time of bariatric surgery
Procedure/SurgeryOpportunistic salpingectomy (fallopian tube removal) at time of planned elective bariatric surgery
Treatment groups
Trial outcomes
Primary outcomes
Number of participants that successfully undergo opportunistic salpingectomy at time of their bariatric surgery
Secondary outcomes
Length of hospital stay
Safety outcome measure
30-day hospital readmission rate
Safety outcome measure. As indicated by any return to hospital with an inpatient stay in the 30 days following discharge from their surgery.
Blood transfusion
Safety outcome measure. As measured by any whole blood or blood parts administered to a patient's bloodstream
Surgical site infection
Safety outcome measure. Defined as any infection that develops at the site of the surgical incision within 30 days that requires treatment.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: